Genital Herpes News and Research

RSS

Male circumcision reduces risk of herpes simplex virus type 2 and human papillomavirus

Heterosexual men who undergo medical circumcision can significantly reduce their risk of acquiring two common sexually transmitted infections - herpes simplex virus type 2 (HSV-2), the cause of genital herpes, and human papillomavirus (HPV), which can cause cancer and genital warts, according to a report in the March 26 issue of the New England Journal of Medicine (NEJM).

26 Mar 2009

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

10 Feb 2009

Gene-targeting approach for herpes treatment

A new therapy being developed at the University of Florida could, in time, produce another weapon for the fight against herpes.

3 Feb 2009

Topical microbicide protects against genital herpes

A topical microbicide that silences two genes can safely protect against genital herpes infection for as long as one week, according to a joint study by researchers at the Albert Einstein College of Medicine of Yeshiva University and Harvard Medical School.

21 Jan 2009

Starpharma's VivaGelR patent approved in Japan

Starpharma Holdings Limited today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.

29 Oct 2008

Deadly virus scrumpox a threat to rugby players wrestlers

Rugby players and wrestlers may be at risk of a potentially serious skin disease called "scrumpox".

29 Sep 2008

Herpes drug Acyclovir could help control HIV

Acyclovir -- a low-cost, generic drug used to treat herpes -- also might help control HIV in people living with both viruses, according to a study published Wednesday in the journal ell Host and Microbe, Reuters reports.

15 Sep 2008

Starpharma, SSL International reach marketing agreement over VivaGel condoms

The Australia-based Starpharma on Tuesday announced that its VivaGel-coated condom will be sold by SSL International, the owner of the Durex condom brand, Bloomberg reports.

11 Sep 2008

Herpes virus changes anti-herpes drug acyclovir to form that hinders AIDS virus

The drug acyclovir has long been used to suppress outbreaks of oral and genital herpes. Herpes viruses change acyclovir to a form that prevents them from reproducing.

10 Sep 2008

VivaGel coated condoms - Starpharma and SSL International in business

Starpharma Holdings Limited has announced that a full licence agreement has been signed with SSL International plc in relation to the VivaGel coated condom. SSL manufactures and sells Durex condoms, the market-leading condom brand worldwide.

9 Sep 2008

Experts say male circumcision the key to beating AIDS

Experts say while no cure or vaccine for AIDS exists male circumcision could be the key to driving the epidemic into a declining state and closer to extinction.

5 Aug 2008

Antiretroviral therapy as an aid to HIV prevention

The widespread use of highly active antiretroviral therapy may reduce the incidence of HIV in individuals and populations but has been overlooked by public health as a prevention strategy, write Dr. Julio Montaner and colleagues in the Canadian Medical Association Journal.

30 Jun 2008

Treating genital herpes does not reduce eisk of HIV

Treating genital herpes does not reduce the risk of HIV, according to a study published on Friday in the journal Lancet, the AP/Newsweek reports (Cheng, AP/Newsweek, 6/19). Herpes simplex virus-2 has been shown to increase the risk of HIV by as much as threefold, so the researchers examined whether treating HSV-2 might reduce the risk of HIV, Bloomberg reports.

24 Jun 2008

The 'Big Apple' - not the place to be sassy and single!

According to official statistics, living in New York City is risky in more ways than one.

11 Jun 2008

Starpharma reports positive VivaGel clinical study results

Starpharma Holdings Limited today announced positive results of a clinical trial that achieved all its objectives demonstrating that 3% SPL7013 Gel (VivaGel) was safe and well-tolerated in sexually abstinent women when administered vaginally, twice daily for 14 days.

11 May 2008